<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-8 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-8</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-8</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of mechanisms, molecular mediators, and experimental/clinical evidence that explain preferential metastatic organotropism (organ-specific metastasis), including seed/soil compatibility, circulation and arrest, extravasation, immune interactions, and pre-metastatic niche formation, along with which primary cancers and target organs are involved.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>primary_cancer_type</strong></td>
                        <td>str</td>
                        <td>Primary tumor/cancer type studied (e.g., prostate adenocarcinoma, breast cancer, NSCLC, SCLC, melanoma).</td>
                    </tr>
                    <tr>
                        <td><strong>metastatic_target_organ</strong></td>
                        <td>str</td>
                        <td>Organ/site of preferential metastasis discussed (e.g., bone, brain, adrenal gland, liver, lung, lymph node).</td>
                    </tr>
                    <tr>
                        <td><strong>organotropism_pattern_statement</strong></td>
                        <td>str</td>
                        <td>Concise statement of the reported organotropism pattern (e.g., 'prostate cancer preferentially metastasizes to bone'; include any quantitative incidence if stated).</td>
                    </tr>
                    <tr>
                        <td><strong>proposed_mechanism_category</strong></td>
                        <td>str</td>
                        <td>High-level mechanism category as framed by the paper (e.g., seed-and-soil compatibility, pre-metastatic niche, chemokine/chemotaxis, adhesion/integrins/selectins, vascular/flow & mechanical trapping, barrier crossing/BBB, metabolic adaptation, immune evasion, stromal/osteoclast-osteoblast coupling, exosome-mediated organ targeting).</td>
                    </tr>
                    <tr>
                        <td><strong>molecular_mediators_tumor_intrinsic</strong></td>
                        <td>list[str]</td>
                        <td>Tumor-cell intrinsic genes/proteins/pathways implicated in organotropism (e.g., CXCR4, ITGAV/ITGB3, VCAM1, MMPs, ST6GALNAC5, COX2/PTGS2, ANGPTL4, RANK, PTHrP; list as reported).</td>
                    </tr>
                    <tr>
                        <td><strong>molecular_mediators_host_microenvironment</strong></td>
                        <td>list[str]</td>
                        <td>Host/organ microenvironment factors implicated (e.g., CXCL12/SDF-1, RANKL, TGF-Î², BMPs, osteopontin, endothelial adhesion molecules, astrocyte/microglia factors, bone-derived growth factors).</td>
                    </tr>
                    <tr>
                        <td><strong>cell_types_involved</strong></td>
                        <td>list[str]</td>
                        <td>Key cell types reported to mediate organotropism (e.g., endothelial cells, osteoblasts, osteoclasts, bone marrow stromal cells, astrocytes, microglia, neutrophils, macrophages, platelets, CAFs).</td>
                    </tr>
                    <tr>
                        <td><strong>circulation_arrest_extravasation_factors</strong></td>
                        <td>str</td>
                        <td>Any described factors affecting CTC survival, vascular arrest, adhesion, and extravasation in the target organ (e.g., specific integrins/selectins, platelet cloaking, permeability factors, organ-specific endothelium).</td>
                    </tr>
                    <tr>
                        <td><strong>pre_metastatic_niche_evidence</strong></td>
                        <td>str</td>
                        <td>Evidence/claims for pre-metastatic niche formation in the target organ (e.g., bone marrow-derived cell recruitment, ECM remodeling, inflammatory conditioning), including key mediators if stated.</td>
                    </tr>
                    <tr>
                        <td><strong>exosome_or_EVs_role</strong></td>
                        <td>str</td>
                        <td>Any claims/evidence that tumor-derived exosomes/extracellular vesicles determine organotropism (e.g., integrin 'zip codes', organ-specific uptake), including named cargo or surface molecules.</td>
                    </tr>
                    <tr>
                        <td><strong>metabolic_or_niche_adaptation</strong></td>
                        <td>str</td>
                        <td>Any metabolic, epigenetic, or phenotypic adaptations enabling growth in the target organ (e.g., lipid utilization in brain, oxidative stress programs, osteomimicry markers).</td>
                    </tr>
                    <tr>
                        <td><strong>immune_interactions</strong></td>
                        <td>str</td>
                        <td>Immune mechanisms linked to organotropism (e.g., immune suppression in niche, specific myeloid recruitment, NK/T cell effects, organ-specific immune microenvironments).</td>
                    </tr>
                    <tr>
                        <td><strong>experimental_model</strong></td>
                        <td>str</td>
                        <td>Model system used (e.g., mouse intracardiac injection, orthotopic xenograft, syngeneic model, genetically engineered mouse model, patient-derived xenograft, organ-on-chip, in vitro BBB model).</td>
                    </tr>
                    <tr>
                        <td><strong>study_design_and_cohort</strong></td>
                        <td>str</td>
                        <td>If clinical/omics: cohort type and size, data source (e.g., autopsy series, metastasis biopsies, TCGA, MSK-IMPACT), and key comparison (e.g., bone vs non-bone metastases).</td>
                    </tr>
                    <tr>
                        <td><strong>key_results_quantitative</strong></td>
                        <td>str</td>
                        <td>Main quantitative results supporting organotropism mechanism (e.g., effect sizes, hazard ratios, percent change in metastatic burden, p-values), with units and context.</td>
                    </tr>
                    <tr>
                        <td><strong>causal_intervention_and_effect</strong></td>
                        <td>str</td>
                        <td>Any perturbation demonstrating causality (e.g., gene knockdown/overexpression, blocking antibody, inhibitor, knockout host) and its effect on organ-specific metastasis.</td>
                    </tr>
                    <tr>
                        <td><strong>alternative_explanations_or_confounders</strong></td>
                        <td>str</td>
                        <td>Mentions of competing explanations or confounders (e.g., vascular anatomy and blood flow patterns, detection/surveillance bias, treatment effects, organ size/perfusion, time-to-detection).</td>
                    </tr>
                    <tr>
                        <td><strong>organ_specific_barriers_and_routes</strong></td>
                        <td>str</td>
                        <td>Any organ-specific physical/biological barriers and dissemination routes discussed (e.g., BBB, fenestrated endothelium in liver/adrenal, Batson venous plexus for spine/bone).</td>
                    </tr>
                    <tr>
                        <td><strong>clinical_implications_biomarkers_targets</strong></td>
                        <td>str</td>
                        <td>Any proposed biomarkers predicting organotropism or therapeutic targets/interventions to prevent organ-specific metastasis (e.g., CXCR4 inhibitors, RANKL blockade, integrin targeting).</td>
                    </tr>
                    <tr>
                        <td><strong>limitations_notes</strong></td>
                        <td>str</td>
                        <td>Key limitations noted by authors that would affect theory-building (e.g., model constraints, small cohorts, correlational evidence, generalizability across cancers).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>